X4 Pharmaceuticals, Inc. (XFOR) News
Track canonical SquawkNews coverage tagged to XFOR, X4 Pharmaceuticals, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 10 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
X4 Pharmaceuticals Phase III enrollment nears completion for mavorixafor
Mavorixafor’s Phase III trial for chronic neutropenia is on track with a reduced enrollment target and strong FDA alignment. X4 Pharmaceuticals says operational changes improved enrollment, with a new study to address G-
REGULATION | Sep 10, 2026, 02:41 PM UTC
L
XFOR nears Phase III mavorixafor enrollment completion
XFOR says its Phase III trial for chronic neutropenia is on track to complete enrollment by year-end. Top-line data is expected in early 2028, with a new G-CSF titration study planned and commercial launch targeted for l
EQUITY | Sep 10, 2026, 02:15 PM UTC
L
X4 Pharmaceuticals to join fireside chat at Wells Fargo Healthcare Conference
X4 Pharmaceuticals said management will participate in a fireside chat at the 2026 Wells Fargo Healthcare Conference on Thursday, September 10.
EQUITY | Sep 09, 2026, 11:03 AM UTC
L
XFOR - X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
XFOR - X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
EQUITY | Sep 09, 2026, 11:00 AM UTC
L
X4 posts updated presentation, flags 4WARD timelines
X4 posted an updated corporate presentation saying full enrollment for its pivotal 4WARD Phase 3 study is expected in Q4 2026, with topline data expected in H1 2028.
REGULATION | Sep 09, 2026, 10:04 AM UTC
M
FDA accepts reduced sample size for X4’s 4WARD Phase 3
X4 Pharmaceuticals said the FDA agreed to reduce 4WARD Phase 3 to 126 patients, accepted the proposed safety database, and the company targets enrollment completion by year-end 2026.
REGULATION | Sep 08, 2026, 11:23 AM UTC
M
X4 Pharmaceuticals gets positive FDA input on 4WARD Phase 3 trial
FDA agreed to a reduced sample size for X4 Pharmaceuticals’ Global 4WARD Phase 3 chronic neutropenia trial. Enrollment is expected to complete by year-end 2026, with topline data due in H1 2028.
REGULATION | Sep 08, 2026, 11:07 AM UTC
M
X4 Pharmaceuticals announces positive FDA Type C meeting outcome
X4 Pharmaceuticals said its FDA Type C meeting outcome was positive.
REGULATION | Sep 08, 2026, 11:01 AM UTC
L
X4 Pharmaceuticals announces inducement grants under Nasdaq Rule 5635(c)(4)
X4 Pharmaceuticals said it is announcing inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:31 PM UTC
H
Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of Airsculpt Technologies Inc (NASDAQ: AIRS ) fell sharply in pre-market trading following second-quarter results. Ai
EARNINGS | Aug 10, 2026, 12:02 PM UTC